DARK Classics in Chemical Neuroscience: Fentanyl

被引:57
作者
Burns, S. Mallory [1 ]
Cunningham, Christopher W. [2 ]
Mercer, Susan L. [1 ,3 ]
机构
[1] Lipscomb Univ, Dept Pharmaceut Sci, Coll Pharm, Nashville, TN 37204 USA
[2] Concordia Univ, Dept Pharmaceut Sci, Wisconsin Sch Pharm, Mequon, WI 53097 USA
[3] Vanderbilt Univ, Dept Pharmacol, Med Ctr, Nashville, TN 37232 USA
来源
ACS CHEMICAL NEUROSCIENCE | 2018年 / 9卷 / 10期
关键词
Fentanyl; opioid; analgesic; pain; designer drug; MU-OPIOID RECEPTOR; INDUCED RESPIRATORY DEPRESSION; 4-ANILIDOPIPERIDINE ANALGESICS; PHARMACOLOGICAL-PROPERTIES; SYNTHETIC ANALGESICS; CONTINUOUS-INFUSION; UNITED-STATES; IN-VITRO; MORPHINE; NALOXONE;
D O I
10.1021/acschemneuro.8b00174
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Fentanyl rose to prominence as an alternative analgesic to morphine nearly 50 years ago; today, fentanyl has re-emerged as a dangerous recreational substance. The increased potency and analgesic effect of fentanyl are advantageous in the treatment of pain but are also responsible for the rise in unintentional opioid overdose deaths. In response to this crisis, fentanyl, its analogues, and even precursors are under heightened regulatory scrutiny. Despite this controversial history, derivatization of fentanyl has resulted in numerous synthetic analogues that provide valuable insights into opioid receptor binding and signaling events. In this review, the impact of fentanyl on chemical neuroscience is shown through its synthesis and properties, manufacturing, metabolism, pharmacology, approved and off-label indications, adverse effects, and the responsibility it has in the opioid epidemic.
引用
收藏
页码:2428 / 2437
页数:19
相关论文
共 129 条
  • [1] AMIN HM, 1995, J PHARMACOL EXP THER, V274, P34
  • [2] [Anonymous], 2017, OP OV
  • [3] [Anonymous], 2016, DEA REL 2016 DRUG TH
  • [4] [Anonymous], 2011, HIGHL PRESCR INF FEN, P1
  • [5] [Anonymous], 2017, FENT BRIEF GUID 1 RE
  • [6] [Anonymous], 2018, DRUG REC FENT AN
  • [7] [Anonymous], 2016, FENT BRIEF DESCR
  • [8] [Anonymous], 2018, US DRUG ENF ADM EM S
  • [9] [Anonymous], 2018, STAND NAM SUBST FENT
  • [10] [Anonymous], 2016, HIGHL PRESCR INF DUR, P1